Bio-Rad Laboratories financials
$379.55+0.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B | $2.31B | $2.29B | $2.16B | $2.07B |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B | $1.26B | $1.22B | $1.19B | $1.14B |
| Gross margin | 51.9% | 53.7% | 53.4% | 55.9% | 56.1% | 56.5% | 54.4% | 53.4% | 55.0% | 55.0% |
| Operating income | $220.0M | $269.0M | $337.8M | $482.6M | $500.3M | $421.3M | $229.7M | -$103.3M | $119.3M | $55.7M |
| Net income | $759.9M | -$1.84B | -$637.3M | -$3.63B | $4.25B | $3.81B | $1.76B | $365.6M | $122.2M | $26.0M |
| Net margin | 29.4% | −71.9% | −23.9% | −129.5% | 145.6% | 149.8% | 76.1% | 16.0% | 5.7% | 1.3% |
| Diluted EPS | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 | $126.47 | $58.27 | $12.10 | $4.07 | $0.88 |
| EBITDA | $220.0M | $269.0M | $337.8M | $619.9M | $637.9M | $559.9M | $363.9M | $327.3M | $279.5M | $118.0M |
| Operating cash flow | $532.2M | $455.2M | $374.9M | $194.4M | $669.5M | $585.0M | $457.9M | $285.5M | $104.1M | $216.1M |
| Free cash flow | $374.6M | $289.6M | $218.2M | $81.6M | $535.8M | $476.4M | $359.4M | $155.7M | -$7.2M | $74.6M |
| Diluted shares | 27.3M | 28.2M | 29.2M | 29.8M | 30.2M | 30.2M | 30.2M | 30.2M | 30.0M | 29.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $529.8M | $488.1M | $403.8M | $434.2M | $470.8M | $662.2M |
| Short-term investments | $1.01B | $1.18B | $1.20B | $1.36B | $399.1M | $328.9M |
| Total debt | $1.20B | $1.20B | $1.20B | $1.20B | $11.0M | $14.1M |
| Total assets | $10.58B | $9.36B | $12.30B | $13.50B | $17.80B | $12.97B |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | $4.11B | $3.09B |
| Shareholders' equity | $7.45B | $6.57B | $8.74B | $9.62B | $13.69B | $9.88B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology